Yana V. Vishnevskaya

Yana V. Vishnevskaya

Auto-generated profile, based on publicly available information

Yana V. Vishnevskaya

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2019 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
TBTatiana S. Belysheva
Tatiana S. Belysheva
YVYana V. Vishnevskaya
Yana V. Vishnevskaya
TNTatiana Nasedkina
Tatiana Nasedkina
MEMarina Emelyanova
Marina Emelyanova
IAIvan S. Abramov
Ivan S. Abramov
MAMamed D. Aliev
Mamed D. Aliev
A giant congenital melanocytic nevus (GCMN) is found in 0.1% of live-born infants. If present, the lesion has a chance of about 6% to develop into malignant melanoma. Both children and adults can be affected by malignant melanoma arising in a giant congenital nevus. Up to 95% of GCMNs harbor NRAS mutations, and mutations in the BRAF, MC1R, TP53, and GNAQ genes have also been described. The individualization of therapy is required, but diagnostic and prognostic criteria remain controversial. We report two cases: 1) melanoma arising in a giant congenital nevus during the first month of life complicated with neurocutaneous melanosis (NCM), and 2) melanoma arising in a giant congenital nevus during the first 6 months of life. Pathology, immunohistochemistry, and genetic analyses of tumor tissue were performed. The first case revealed only a non-pathogenic P72R polymorphism of the TP53 gene in the homozygote condition. For the second case, a Q61K mutation was detected in the NRAS gene. Malignant melanoma associated with GCMN is rare and therefore poorly understood. Outcomes have been linked to the stage at diagnosis, but no additional pathological prognostic factors have been identified. The most frequent genetic event in giant CMNs is NRAS mutations, which was discovered in one of our cases. To accumulate evidence to improve disease prognosis and outcomes, children with congenital melanocytic nevus should be included in a systemic follow-up study from birth.

30 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
EZEkaterina Zelenova
Ekaterina Zelenova
TBTatiana Belysheva
Tatiana Belysheva
Denis SofronovDenis Sofronov
Denis Sofronov
VSVera Semenova
Vera Semenova
GRGalimat Radjabova
Galimat Radjabova
TNTatiana Nasedkina
Tatiana Nasedkina
Background/Objectives: Metastatic colorectal cancer remains a fatal disease, with a 5-year survival rate lower than 15%. The most common metastatic sites are the lungs and the liver, while skin metastases are very rare and often indicate a poor prognosis with a lower survival rate. Methods. Herein, we present the clinical case of a 62-year-old female patient with rectal cancer metastases to the skin of the anogenital and abdominal regions, diagnosed 2 years after completion of treatment of the underlying disease. Results: Histological examination of the skin lesions revealed adenocarcinoma, and expression of the same immunohistochemical markers was also found in the primary tumor and in the cutaneous metastases. However, next-generation sequencing demonstrated differences in the mutational profiles of the primary tumor and metastasis to the skin. Somatic mutations in the APC, TP53, and PTPN11 genes were revealed in primary rectal adenocarcinoma, but another pathogenic TP53 mutation and a frameshift variant in the DYNC1I1 gene were found in cutaneous metastases. The patient underwent several courses of FOLFOX6 chemotherapy in combination with bevacizumab, but the treatment was unsuccessful. An analysis of 50 clinical cases from the literature concerning various manifestations of cutaneous metastases of rectal cancer showed a median survival of 8.5 months from the time of detection of the skin lesions. Conclusions: In this regard, careful skin examination of patients with rectal cancer and timely detection of cutaneous metastases are essential steps in the follow-up of patients who have undergone treatment of the primary tumor.

1 July 2003 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
VZV. V. Zemlyakova
V. V. Zemlyakova
AZA. I. Zhevlova
A. I. Zhevlova
VSVladimir Strelnikov
Vladimir Strelnikov
LLL. N. Lyubchenko
L. N. Lyubchenko
MSM. A. Schabanov
M. A. Schabanov
MNM. V. Nemtsova
M. V. Nemtsova

7 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
EZEkaterina Zelenova
Ekaterina Zelenova
TBTatiana Belysheva
Tatiana Belysheva
ESElena Sharapova
Elena Sharapova
IBIrina Barinova
Irina Barinova
AFAlexandra Fedorova
Alexandra Fedorova
TNTatiana Nasedkina
Tatiana Nasedkina
Background/Objectives: Cowden syndrome (or PTEN hamartoma tumor syndrome) (CS/PHTS) belongs to a group of inherited disorders associated with the development of multiple hamartomas. The clinical presentation of patients may include dysmorphic facial features, macrocephaly, developmental delay, and multiple benign and malignant tumors of various localizations. At the same time, only thyroid cancer is thought to have an increased risk in childhood. Skin lesions in CS/PHTS occur in 90–100% of patients and include multiple tricholemmoma, papilloma, acral keratosis, pigmentation changes, as well as rarer forms like vascular malformations, fibromas, neuromas, melanoma, and basal cell carcinoma. Methods: Next-generation sequencing and Sanger sequencing were used to search for PTEN genetic variants. A histological and immunohistochemical examination of tumor biopsies and skin lesions was performed. Results: A total of 13 patients from six families with CS/PHTS, including 10 children, were described. Seven pediatric patients belonged to families with paternal transmission of the PTEN pathogenic variants, while three others were de novo cases. Atypical manifestations in CS/PHTS were diffuse large B-cell lymphoma in one adult, a renal cell carcinoma, three germ cell tumors, and a linear epidermal nevus in pediatric patients. A literature review of the identified pathogenic variants in the PTEN gene was performed, assessing their clinical significance and analyzing the traditional and modified diagnostic criteria as applied to the pediatric population. Conclusions: Taking into account the low incidence of CS/PHTS, the data presented significantly expand our current understanding of this disease and guide physicians to consider a wider range of possible malignant neoplasms in pediatric patients with CS/PHTS.

19 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TBTatiana Belysheva
Tatiana Belysheva
TNTatiana Nasedkina
Tatiana Nasedkina
EZEkaterina Zelenova
Ekaterina Zelenova
VSVera Semenova
Vera Semenova
NSNatalia Semenova
Natalia Semenova
SVSvetlana Varfolomeeva
Svetlana Varfolomeeva
Mosaic RASopathies are rare conditions caused by postzygotic mutations in RAS/MAPK signaling pathway genes arising during embryonic development. They are mainly characterized by a combination of epidermal nevi with extra-cutaneous manifestations. Choosing between different entities can be challenging because of their substantial clinical and genetic overlap. Our aim was to demonstrate the importance of genetic background in accurate diagnosis and further prognostic assessment of disease progression by analyzing genotype–phenotype correlations within this clinical group. The study enrolled 18 patients (10 males, 8 females) aged from 1 month to 21 years with congenital nevi of craniofacial localization and variable extracutaneous abnormalities. DNA isolated from peripheral blood lymphocytes and affected tissues (nevus, tumor) was analyzed using a targeted next-generation sequencing (NGS) panel covering RAS/MAPK pathway genes, followed by Sanger sequencing. Eight patients were diagnosed with Schimmelpenning–Feuerstein–Mims syndrome caused by postzygotic mutations in the HRAS (n=4) or KRAS (n=4) genes. Seven patients were clinically diagnosed with phacomatosis pigmentokeratotica, and mosaic mutations were identified in the HRAS (n=4), KRAS (n=2), or BRAF (n=1) genes. Two patients with similar phenotypes carried somatic mutations in the PIK3CA and FGFR2 genes, respectively, and in one case no mutation was detected in the affected skin. We compared the spectrum of extracutaneous anomalies depending on the mutation in a specific gene by combining our data with data from other clinical cases of mosaic RASopathies described in the literature. In summary, 53 cases with HRAS postzygotic mutations and 41 cases with KRAS mutations were involved in the analysis of genotype–phenotype correlations. Hypophosphatemic rickets and malignant tumors were associated with mutations in the HRAS gene, while ophthalmological, neurological, cardiovascular, and renal disorders were more common in KRAS-mutant patients. Thus, genetic testing of affected tissue is essential for accurate diagnosis of these mosaic disorders. Taking into account clinical manifestations and the identified genotype–phenotype correlations may further assist in prognosis and patient management.

20 January 2022 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
TBT. S. Belysheva
T. S. Belysheva
TNTatiana Nasedkina
Tatiana Nasedkina
TVTimur Valiev
Timur Valiev
NMN. V. Matinyan
N. V. Matinyan
OMO. A. Malikhova
O. A. Malikhova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
Синдром Пейтца–Егерса: мультидисциплинарный подход в диагностике на примере клинического случая